Most Read Articles
Elvira Manzano, 13 Sep 2017
Tisagenlecleucel, now US FDA approved, has made history as the first ever chimeric antigen receptor (CAR) T-cell therapy for B-cell precursor acute lymphoblastic leukaemia (ALL) – a breakthrough that has the potential to transform treatment for blood cancers that have not responded to standard therapies.
Christina Lau, 09 May 2017

Treatment with osimertinib significantly improves symptoms in patients with advanced non-small-cell lung cancer (NSCLC), according to new data from the phase III AURA3 trial presented at the European Lung Cancer Conference (ELCC) 2017.

Coaching and question prompt list improve patient-oncologist communication

09 Feb 2017
Medical Enquiries from Friends and Family: Setting Boundaries
The combination of previsit patient coaching sessions and a question prompt list (QPL) leads to better patient-oncologist communication in advanced cancer, a study shows.

The cluster randomized controlled trial included 170 patients with advanced nonhaematologic cancer and their caregivers. The study participants were recruited from practices of 24 oncologists in New York. The intervention arm of the study included 12 oncologists who underwent individualized communication training and 84 patients who had individualized previsit coaching sessions with QPL. The other 12 oncologists and 86 patients in the control group received no interventions.

Results showed that 70.2 percent of patients in the intervention group brought up QPL-related topics compared with only 32.6 percent of patients in the control group (p<0.001). More patients in the intervention group (16.7 percent) asked about prognosis compared to the control group (5.8 percent; p=0.03).

A majority of the topics of interest identified during the previsit coaching were QPL-related and among these, 12.7 percent  involved prognosis.

Combining previsit individualized coaching and QPL intervention resulted in a more effective patient-oncologist dialogue. This helped advanced cancer patients and their caregivers identify and ask about topics of concern.
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Elvira Manzano, 13 Sep 2017
Tisagenlecleucel, now US FDA approved, has made history as the first ever chimeric antigen receptor (CAR) T-cell therapy for B-cell precursor acute lymphoblastic leukaemia (ALL) – a breakthrough that has the potential to transform treatment for blood cancers that have not responded to standard therapies.
Christina Lau, 09 May 2017

Treatment with osimertinib significantly improves symptoms in patients with advanced non-small-cell lung cancer (NSCLC), according to new data from the phase III AURA3 trial presented at the European Lung Cancer Conference (ELCC) 2017.